MA26651A1 - Composition neuroprotectrice pour la prevention et / ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression - Google Patents

Composition neuroprotectrice pour la prevention et / ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression

Info

Publication number
MA26651A1
MA26651A1 MA25627A MA25627A MA26651A1 MA 26651 A1 MA26651 A1 MA 26651A1 MA 25627 A MA25627 A MA 25627A MA 25627 A MA25627 A MA 25627A MA 26651 A1 MA26651 A1 MA 26651A1
Authority
MA
Morocco
Prior art keywords
nervous
depression
anxiety
prevention
treatment
Prior art date
Application number
MA25627A
Other languages
English (en)
Inventor
Cavazza Claudio
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of MA26651A1 publication Critical patent/MA26651A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA25627A 1998-06-25 1999-06-15 Composition neuroprotectrice pour la prevention et / ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression MA26651A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98RM000425A IT1299195B1 (it) 1998-06-25 1998-06-25 Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati

Publications (1)

Publication Number Publication Date
MA26651A1 true MA26651A1 (fr) 2004-12-20

Family

ID=11406010

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25627A MA26651A1 (fr) 1998-06-25 1999-06-15 Composition neuroprotectrice pour la prevention et / ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression

Country Status (26)

Country Link
US (1) US6346282B1 (fr)
EP (1) EP1089744B1 (fr)
JP (1) JP2002518438A (fr)
KR (1) KR20010053059A (fr)
CN (1) CN1307479A (fr)
AT (1) ATE228369T1 (fr)
AU (1) AU756542B2 (fr)
BR (1) BR9912179A (fr)
CA (1) CA2334858C (fr)
DE (1) DE69904173T2 (fr)
DK (1) DK1089744T3 (fr)
EE (1) EE200000729A (fr)
ES (1) ES2188178T3 (fr)
HU (1) HUP0102546A3 (fr)
IL (1) IL140159A0 (fr)
IS (1) IS5765A (fr)
IT (1) IT1299195B1 (fr)
MA (1) MA26651A1 (fr)
NO (1) NO20006430L (fr)
NZ (1) NZ508882A (fr)
PL (1) PL194177B1 (fr)
PT (1) PT1089744E (fr)
SK (1) SK19302000A3 (fr)
TN (1) TNSN99135A1 (fr)
TR (1) TR200003736T2 (fr)
WO (1) WO1999066914A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
DE10015617A1 (de) * 2000-03-29 2001-10-04 Peter Laetzsch Migränemittel
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
IT1317035B1 (it) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa Integratore ad attivita' antiossidante comprendente unaalcanoilcarnitina ed una associazione di polifenoli estratti dal
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
DE10213571A1 (de) * 2002-03-26 2003-10-23 Lichtwer Pharma Ag Pflanzenextrakte und deren Anwendung
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
ATE437884T1 (de) * 2003-05-29 2009-08-15 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070065486A1 (en) * 2004-05-21 2007-03-22 Migco Limited Migraine remedy
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
EP1854486A3 (fr) * 2006-03-14 2010-06-02 Wilfried P. Bieger Utilisation de dérivés de neurotransmetteurs destinée à la fabrication d'agents de traitement des perturbations neuroendocrines liées à la santé
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
AU2009315771A1 (en) * 2008-11-11 2010-05-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
BRPI0900614A2 (pt) 2009-02-13 2011-06-28 Univ Fed Do Rio Grande Do Sul Ufrgs extrato vegetal neuroativo, composição farmacêutica compreendendo o mesmo e processo para sua produção
SG185692A1 (en) * 2010-06-16 2013-01-30 Sigma Tau Ind Farmaceuti Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue
CA2807510A1 (fr) 2010-08-05 2012-02-09 Case Western Reserve University Inhibiteurs de l'erk destines a traiter des troubles du developpement de la connectivite neuronale
JP2014145857A (ja) 2013-01-28 2014-08-14 Sony Corp 表示装置およびその製造方法、並びに電子機器
EA201700348A1 (ru) * 2015-02-04 2018-02-28 Общество С Ограниченной Ответственностью "Консорциум-Пик" Способ повышения эффективности терапии антидепрессантом в комплексной антидепрессивной терапии и фармацевтическая комбинация

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
DE4239959A1 (de) * 1992-11-27 1994-06-01 Schwabe Willmar Gmbh & Co Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5911992A (en) * 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia

Also Published As

Publication number Publication date
PT1089744E (pt) 2003-04-30
IT1299195B1 (it) 2000-02-29
HUP0102546A2 (hu) 2001-10-28
DE69904173T2 (de) 2003-08-28
WO1999066914A3 (fr) 2000-04-06
TNSN99135A1 (fr) 2005-11-10
NZ508882A (en) 2002-06-28
SK19302000A3 (sk) 2001-09-11
TR200003736T2 (tr) 2001-06-21
KR20010053059A (ko) 2001-06-25
NO20006430D0 (no) 2000-12-15
ES2188178T3 (es) 2003-06-16
DK1089744T3 (da) 2003-03-24
AU4391099A (en) 2000-01-10
CA2334858A1 (fr) 1999-12-29
EP1089744A2 (fr) 2001-04-11
CN1307479A (zh) 2001-08-08
CA2334858C (fr) 2010-08-24
HUP0102546A3 (en) 2003-08-28
IL140159A0 (en) 2002-02-10
ATE228369T1 (de) 2002-12-15
JP2002518438A (ja) 2002-06-25
EE200000729A (et) 2002-06-17
NO20006430L (no) 2001-02-21
AU756542B2 (en) 2003-01-16
IS5765A (is) 2000-12-08
ITRM980425A0 (it) 1998-06-25
PL345279A1 (en) 2001-12-03
EP1089744B1 (fr) 2002-11-27
WO1999066914A2 (fr) 1999-12-29
DE69904173D1 (de) 2003-01-09
ITRM980425A1 (it) 1999-12-25
BR9912179A (pt) 2001-04-10
US6346282B1 (en) 2002-02-12
PL194177B1 (pl) 2007-05-31

Similar Documents

Publication Publication Date Title
MA26651A1 (fr) Composition neuroprotectrice pour la prevention et / ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression
MA26655A1 (fr) Composition pour prevention et/ou traitement d'osteoporose et d'alterations dues au syndrome menopause
BRPI0006634B8 (pt) composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
AU2001257451A8 (en) Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
TNSN04191A1 (fr) Composes qui modulent l'activite de ppar et procedes pour leur preparation
MA26889A1 (fr) Composition pharmaceutique pour le traitement de la douleur aigue chronique et/ ou neuropathique et des migraines
DE60130466D1 (de) Antipruritische zusammensetzungen und die wundheilung fördernde zusammensetzungen
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
DE602004013146D1 (de) Zusammensetzungen zur prävention und behandlung von erkältung und grippe-ähnlichen symptomen, die cheliertes zink enthalten
DZ3027A1 (fr) Composés et procédés pour le traitement de l'asthme, de l'allergie et des troubles inflammatoires.
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
ES2162520T3 (es) Medicamentos basados en hiperforina y/o extractos de hiperforina.
BRPI0418749A (pt) composição herbal
MA27690A1 (fr) Composition pharmaceutique androgene et procede pour le traitement de la depression.
FR2786096B1 (fr) Composition pour la prevention et le traitement topique de la cellulite
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit
MY130725A (en) Composition and method for treating allergic diseases
FR2760363B1 (fr) Composition pour le traitement topique des affections de la peau et des phaneres
NO20020313D0 (no) Behandling av angiogenese avhengige tilstander med dekstrinsulfat
CO5140080A1 (es) Composicion y metodo para tratar enfermedades alergicas dades respiratorias que comprende combinaciones de antagonis tas de receptores de neuroquinina y leucotrieno.
FR2821554B1 (fr) Compositions topiques contenant au moins un derive d'ethanolamine pour le traitement ou la prevention des dommages de la peau associes au vieillissement de la peau et procedes comestique associes
FR2750332B1 (fr) Composition pour la prevention et le traitement topique de la cellulite
MY128938A (en) A herbal composition
FR2865735B1 (fr) Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese